Using furosemide to predict successful recovery from kidney treatment
Evaluation of the Furosemide Stress Test to Predict Successful Liberation From Renal Replacement Therapy in Critically Ill Patients
Centre Hospitalier Universitaire Vaudois · NCT05612490
This study is testing if giving a specific dose of furosemide soon after stopping kidney treatment can help predict if critically ill patients with acute kidney injury will recover successfully.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Vaudois (other) |
| Locations | 1 site (Lausanne, Vaud) |
| Trial ID | NCT05612490 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates whether a standardized dose of furosemide, given within 12 hours after attempting to liberate patients from renal replacement therapy (RRT), can effectively predict successful recovery in critically ill patients with acute kidney injury (AKI). The study aims to standardize the furosemide stress test (FST) to assess diuresis and its correlation with RRT liberation outcomes. By establishing a reliable method for predicting RRT success, the study seeks to improve patient management and prevent complications associated with unsuccessful liberation.
Who should consider this trial
Good fit: Ideal candidates for this study are critically ill patients receiving continuous or intermittent renal replacement therapy for acute kidney injury who are being considered for RRT liberation.
Not a fit: Patients with significant electrolyte disturbances, hemodynamic instability, or those with known furosemide allergies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better patient outcomes by accurately predicting which patients can safely discontinue renal replacement therapy.
How similar studies have performed: While the furosemide stress test has shown promise in predicting AKI progression, its application for predicting RRT liberation has not been formally assessed in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Receiving continuous or intermittent RRT for AKI * Having an indwelling urinary catheter * Clinical decision by physician in charge to attempt RRT liberation * lnformed consent signed by the patient himself / legal representative or authorization received from independent physician Exclusion Criteria: * Electrolyte disturbances or hemodynamic instability precluding the use of furosemide (sodium \> 155 mmol/L and/or potassium \< 3.0 mmol/L and/or metabolic alkalosis \> 7.50 and/or mean arterial pressure \< 60 mmHg) * Known furosemide allergy * Urine output ≥ 100 mL/h for at least two hours * Recent (\< 24 hours) FST * Known end-stage chronic renal disease at ICU admission * Withdrawal of life support decision taken before inclusion * Patient already participating in conflicting research study * Patient having already participated in this current study * Any other contraindication of furosemide
Where this trial is running
Lausanne, Vaud
- Centre Hospitalier Universitaire Vaudois — Lausanne, Vaud, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Antoine Schneider, MD PhD — Centre Hospitalier Universitaire Vaudois
- Study coordinator: Antoine schneider, MD PhD
- Email: antoine.scheider@chuv.ch
- Phone: +41795561902
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Kidney Injury, Renal replacement therapy, Furosemide Stress Test